<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812691</url>
  </required_header>
  <id_info>
    <org_study_id>JWCAR029-003</org_study_id>
    <nct_id>NCT04812691</nct_id>
  </id_info>
  <brief_title>CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ming Ju Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Ming Ju Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, open-label, single-arm, multicenter study to assess the safety and&#xD;
      efficacy of JWCAR029 in adult primary refractory DLBCL subjects in China&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, open-label, single-arm, multicenter study conducted in adult subjects with&#xD;
      primary refractory DLBCL in China to evaluate the safety, efficacy, pharmacokinetics(PK),&#xD;
      pharmacodynamics(PD) of JWCAR029 and collect immune response after JWCAR029 treatment.&#xD;
&#xD;
      One dose level of 1.0 x 10^8 CAR+ T cells is adopted in this study. All sujects will be&#xD;
      followed for 2 years after JWCAR029 infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Types, frequency, and severity of adverse events and laboratory anomalies</measure>
    <time_frame>2 years</time_frame>
    <description>Physiological parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR) in primary refractory DLBCL subjects</measure>
    <time_frame>1 month</time_frame>
    <description>Investigator evaluated CRR in 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) in primary refractory DLBCL subjects</measure>
    <time_frame>1 month</time_frame>
    <description>Investigator evaluated ORR in 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response rate (BORR)</measure>
    <time_frame>2 years</time_frame>
    <description>The best response from the onset of treatment to the onset of disease progression/recurrence or to the onset of another anticancer treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator evaluated CRR</measure>
    <time_frame>3 months</time_frame>
    <description>Complete response rate (CRR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator evaluated ORR (ORR=CR+PR)</measure>
    <time_frame>3 months</time_frame>
    <description>Complete response (CR) + partial response（PR）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from first response(PR or CR) to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete remission (DoCR)</measure>
    <time_frame>up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from complete response (CR) to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from JWCAR029 infusion to first documentation of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete response (TTCR)</measure>
    <time_frame>up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from JWCAR029 infusion to first documentation of CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)- Cmax of JWCAR029</measure>
    <time_frame>up to 1 year after JWCAR029 infusion</time_frame>
    <description>Maximum observed concentration of JWCAR029 in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)- Tmax of JWCAR029</measure>
    <time_frame>up to 1 year after JWCAR029 infusion</time_frame>
    <description>Time to maximum concentration of JWCAR029 in the peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)- AUC of JWCAR029</measure>
    <time_frame>up to 1 year after JWCAR029 infusion</time_frame>
    <description>Area under the concentration vs time curve of JWCAR029</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 2 year after JWCAR029 infusion</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 2 year after JWCAR029 infusion</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of CRP and serum ferritin</measure>
    <time_frame>1 year after JWCAR029 infusion</time_frame>
    <description>Changes of inflammation biomarkers-CRP and serum ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-therapeutic JWCAR029 antibody</measure>
    <time_frame>up to 2 year after JWCAR029 infusion</time_frame>
    <description>The level of anti-therapeutic JWCAR029 antibody after JWCAR029 infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concentration of Car-T cell</measure>
    <time_frame>up to 2 year after JWCAR029 infusion</time_frame>
    <description>The concentration of Car-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of Car-T cell subgroups</measure>
    <time_frame>up to 2 year after JWCAR029 infusion</time_frame>
    <description>The proportion of Car-T cell subgroups after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concentration of CD19 in tumor biopsy samples</measure>
    <time_frame>up to 2 year after JWCAR029 infusion</time_frame>
    <description>The concentration of CD19 in tumor biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of serum cytokines concentration</measure>
    <time_frame>up to 2 year after JWCAR029 infusion</time_frame>
    <description>The change of serum cytokines concentration after JWCAR029 infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>JWCAR029</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The safety and efficacy of JWCAR029 will be evaluated in 1 x 10^8 CAR+T cells dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)</intervention_name>
    <description>Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.</description>
    <arm_group_label>JWCAR029</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years old;&#xD;
&#xD;
          2. Sign on the informed consent;&#xD;
&#xD;
          3. Subject must have histologically confirmed diffuse large B lymphoma and primary&#xD;
             refractory with first-line therapy;&#xD;
&#xD;
          4. Subjects have accessible PET-positive lesion and have measurable CT-positive lesion&#xD;
             according to Lugano Classification;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
          6. Adequate organ function;&#xD;
&#xD;
          7. Adequate vascular access for leukapheresis procedure;&#xD;
&#xD;
          8. Subjects who have previously received CD19 targeted therapy must confirm that lymphoma&#xD;
             lesions still express CD19;&#xD;
&#xD;
          9. Women of childbearing potential must agree to use highly effective methods of&#xD;
             contraception for 1 year after the last dose of JWCAR029;&#xD;
&#xD;
         10. Males who have partners of childbearing potential must agree to use an effective&#xD;
             barrier contraceptive method for 1 year after the last dose of JWCAR029&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received second-line treatment or above&#xD;
&#xD;
          2. CD19 negative&#xD;
&#xD;
          3. Primary CNS lymphoma;&#xD;
&#xD;
          4. History of another primary malignancy that has not been in remission for at least 2&#xD;
             years;&#xD;
&#xD;
          5. Subjects has HBV, HCV, HIV or syphilis infection at the time of screening;&#xD;
&#xD;
          6. Deep venous thrombosis (DVT)/Pulmonary embolism (PE), or DVT/PE requires&#xD;
             anti-coagulation within 3 months prior to signing the ICF;&#xD;
&#xD;
          7. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection;&#xD;
&#xD;
          8. Presence of acute or chronic graft-versus-host disease (GVHD);&#xD;
&#xD;
          9. History of any serious cardiovascular disease or presence of clinically relevant CNS&#xD;
             pathology;&#xD;
&#xD;
         10. Pregnant or nursing women;&#xD;
&#xD;
         11. Subjects using of any chemotherapy, corticisteriod, experiment agents, GVHD therapies,&#xD;
             radiation, allo-HSCT or any other therapies for lymphoma must go through a specific&#xD;
             wash-out period before leukapheresis;&#xD;
&#xD;
         12. Uncontrolled conditions or unwillingness or inability to follow the procedures&#xD;
             required in the protocol;&#xD;
&#xD;
         13. Received CAR T-cell or other genetically-modified T-cell therapy previously.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JWCAR029Medical Shanghai Ming Ju Biotechnology Co., Ltd</last_name>
    <phone>+86 21 50464201</phone>
    <email>JWCAR029Medical@jwtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang university school of medicine first affiliated hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

